Corona of Biologically Synthesized Nanoparticle Provide Better Interface to Trap Monomeric Α-Synuclein in Non-Cytotoxic Amorphous Aggregate Structure

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder, characterized by the degeneration of dopaminergic neurons in the substantia nigra and the abnormal accumulation of Alpha-synuclein (α-syn) aggregates or Lewy bodies, leading to a major loss of motor function. α-Syn is an intrinsically disordered protein, involved in vesicular trafficking and neurotransmitter release. The aggregation of α-syn involves a cascade of structural transition from monomeric protein to the fibrillar form of protein, which is known to be a complex process and is regulated by several intrinsic and extrinsic factors. Currently, nanoparticles have been reported for easy drug delivery as they can easily pass the blood-brain barrier. There are several reports suggesting that the interfaces of metal oxide nanoparticles have a direct effect on α-syn conformation, and it can inhibit the protein amyloidogenesis. Hence, in this report, we screen different ZnONP interfaces (chemically and biologically synthesized) with anti-amyloidogenic potential for α-syn